These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 2671288)

  • 1. Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma.
    Reichman B; Markman M; Hakes T; Hoskins W; Rubin S; Jones W; Almadrones L; Ochoa M; Chapman D; Saigo P
    J Clin Oncol; 1989 Sep; 7(9):1327-32. PubMed ID: 2671288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a Phase II Gynecologic Oncology Group trial.
    Braly PS; Berek JS; Blessing JA; Homesley HD; Averette H
    Gynecol Oncol; 1995 Feb; 56(2):164-8. PubMed ID: 7896179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
    Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
    Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraperitoneal cisplatin and cytarabine in the treatment of refractory or recurrent ovarian carcinoma.
    Markman M; Hakes T; Reichman B; Hoskins W; Rubin S; Jones W; Almadrones L; Yordan EL; Eriksson J; Lewis JL
    J Clin Oncol; 1991 Feb; 9(2):204-10. PubMed ID: 1988569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study.
    Feun LG; Blessing JA; Major FJ; DiSaia PJ; Alvarez RD; Berek JS
    Gynecol Oncol; 1998 Dec; 71(3):410-5. PubMed ID: 9887240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin.
    Markman M; Reichman B; Hakes T; Jones W; Lewis JL; Rubin S; Almadrones L; Hoskins W
    J Clin Oncol; 1991 Oct; 9(10):1801-5. PubMed ID: 1919630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
    Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
    Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
    Louie KG; Ozols RF; Myers CE; Ostchega Y; Jenkins J; Howser D; Young RC
    J Clin Oncol; 1986 Nov; 4(11):1579-85. PubMed ID: 3095501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma.
    Piver MS; Lele SB; Marchetti DL; Baker TR; Emrich LJ; Hartman AB
    J Clin Oncol; 1988 Nov; 6(11):1679-84. PubMed ID: 3183700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of intraperitoneal cisplatin and etoposide as salvage treatment for minimal residual ovarian carcinoma.
    Kirmani S; Lucas WE; Kim S; Goel R; McVey L; Morris J; Howell SB
    J Clin Oncol; 1991 Apr; 9(4):649-57. PubMed ID: 2066761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.
    Morgan RJ; Braly P; Cecchi G; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Parker P; Stein A; Cho J; Smith E; Coluzzi P; Najera L; Johnson D; Womack E; Doroshow JH
    Gynecol Oncol; 1999 Dec; 75(3):419-26. PubMed ID: 10600300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I-II trial of intraperitoneal cisplatin and alpha-interferon in patients with persistent epithelial ovarian cancer.
    Berek JS; Welander C; Schink JC; Grossberg H; Montz FJ; Zigelboim J
    Gynecol Oncol; 1991 Mar; 40(3):237-43. PubMed ID: 2013446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.
    Shapiro F; Schneider J; Markman M; Reichman BS; Venkatraman E; Barakat R; Almadrones L; Spriggs D
    Gynecol Oncol; 1997 Oct; 67(1):39-45. PubMed ID: 9345354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: a Gynecologic Oncology Group study.
    Markman M; Blessing JA; Major F; Manetta A
    Gynecol Oncol; 1993 Aug; 50(2):191-5. PubMed ID: 8375734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraperitoneal high-dose cisplatin and etoposide with systemic thiosulfate protection in second-line treatment of advanced ovarian cancer.
    Malmström H; Rasmussen S; Simonsen E
    Gynecol Oncol; 1993 May; 49(2):166-71. PubMed ID: 8504983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer.
    Markman M; Reichman B; Hakes T; Rubin S; Lewis JL; Jones W; Barakat R; Curtin J; Almadrones L; Hoskins W
    Gynecol Oncol; 1993 Jul; 50(1):100-4. PubMed ID: 8349150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.
    Tournigand C; Louvet C; Molitor JL; Dehni N; Lejeune V; Sezeur A; Pigne A; Marpeau L; Cady J; de Gramont A
    Gynecol Oncol; 2001 Nov; 83(2):198-204. PubMed ID: 11606072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer.
    Howell SB; Kirmani S; Lucas WE; Zimm S; Goel R; Kim S; Horton MC; McVey L; Morris J; Weiss RJ
    J Clin Oncol; 1990 Jan; 8(1):137-45. PubMed ID: 2295904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ip chemotherapy employing a regimen of cisplatin, cytarabine, and bleomycin.
    Markman M; Cleary S; Lucas W; Weiss R; Howell SB
    Cancer Treat Rep; 1986 Jun; 70(6):755-60. PubMed ID: 2425962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I-II study with intraperitoneal cisplatin plus systemic etoposide in patients with minimal residual ovarian cancer.
    Willemse PH; Sleijfer DT; de Vries EG; Boonstra H; Bouma J; Mulder NH
    Eur J Cancer; 1992; 28(2-3):479-81. PubMed ID: 1591067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.